Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease
Sponsor: Columbia University
This PHASE2 trial investigates Huntington's Disease and is currently completed. Columbia University leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Columbia University
- HP Therapeutics Foundation
- Johns Hopkins University
- Massachusetts General Hospital
- University of Alabama at Birmingham
- University of California, San Diego
- University of Iowa
- University of Kansas
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .